• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sage Therapeutics Announces the Appointment of Barry Greene as CEO

    12/16/20 6:30:00 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAGE alert in real time by email

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that, as part of the Company’s plan to accelerate growth and leverage the talents of the leaders in the brain health space, Barry Greene has been appointed chief executive officer. Mr. Greene, who most recently served as president of Alnylam Pharmaceuticals, Inc., from 2007 to September 2020, and as its chief operating officer from 2003 to 2016, will also continue as a member of Sage’s board of directors.

    “Sage is taking on one of the biggest challenges we face today with the urgent and escalating need for more options to transform the lives of millions of patients with debilitating brain health disorders,” said Barry Greene, chief executive officer at Sage. “I am impressed by the groundbreaking and relentless pursuit that Jeff has spearheaded, and one that the entire organization has embraced, to bring a new way of thinking about how we can treat brain health disorders differently. Together, Jeff with his unique neuroscience expertise, and I, along with the talented team at Sage, can leverage our collective strengths in our efforts to bring new options to patients in areas that have been lacking innovation for a very long time. I look forward to being part of such a passionate and committed team as we advance Sage’s multi-franchise strategy and work to deliver on our mission to bring positive impact to the lives of many patients and their families.”

    Dr. Jonas will continue to advance the Company’s mission in the new role of chief innovation officer. In this capacity, he will bring his thought leadership and the creative, innovative thinking for which Sage is known. He will remain a member of the board and will chair Sage’s Science & Technology Forum of the Board. As chief innovation officer, Jeff will focus on his well-recognized expertise — neuroscience, development, and pipeline expansion — bringing to bear in the role his creative thinking and extensive drug development experience.

    “I am optimistic about what we have done to advance breakthrough science with the goal of delivering truly different approaches to treat brain health disorders. We always had the vision of upending the conventional wisdom of how to think about and how to treat these disorders,” said Jeff Jonas, M.D. chief innovation officer and formerly chief executive officer at Sage. “I am proud of the progress we have made on this journey — we took the company from a research organization to a fully integrated biopharmaceutical company with the first approved product for postpartum depression and one of the strongest brain health pipelines in the industry. Our ability to attract Barry’s caliber of talent as our next CEO is a testament to these efforts and he’s committed to continuing to make progress on our journey to provide groundbreaking options for people with brain health disorders. I look forward to working with Barry and the Sage team moving forward and continuing to contribute to Sage’s advancement in my new role.”

    “I’ve known and worked with Barry for 20 years,” said Kevin Starr, chairman of the board at Sage. “His appointment as CEO is the result of thoughtful succession discussions with the Board, with the aim of augmenting the executive bench with a world-class leader committed to moving Sage to the next stage of growth and commercialization. Barry is ideal to lead this mission: he has a significant track record of successfully executing on R&D and commercialization strategies. He has built and grown a multiproduct company and is very familiar with Sage’s business and culture. Having Barry as CEO and Jeff as CInO strengthens Sage for its next evolution.”

    About Barry Greene:
    Barry E. Greene joined the Sage Board of Directors in October 2020 bringing more than 30 years of experience to this position. Prior to Sage, he served as president of Alnylam Pharmaceuticals, Inc., since 2007 and he previously held the position of chief operating officer when he first joined the company in 2003. Prior to his 17 year tenure at Alnylam, Mr. Greene was the general manager of Oncology at Millennium Pharmaceuticals, Inc. where he led the Company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful U.S. Food and Drug Administration approval and launch of VELCADE® (bortezomib) in mid-2003. Prior to joining Millennium in 2001, Mr. Greene served as executive vice president and chief business officer for Mediconsult.com, a healthcare consulting company. Earlier in Mr. Greene’s career, he held multiple leadership positions at AstraZeneca (formerly AstraMerck), and was a partner of Andersen Consulting, where he was responsible for the pharmaceutical/biotechnology marketing and sales practice.

    He received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University’s Fuqua School of Business.

    About Sage Therapeutics
    Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

    Forward-Looking Statements
    Various statements in this release concern Sage's future expectations, plans and prospects, including without limitation: our views and expectations regarding the goals, opportunity, plans, mission and potential for our products, programs and business. These statements constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: success in our earlier clinical trials or non-clinical studies may not be repeated or observed in ongoing or future studies, and ongoing and future clinical and non-clinical results may not meet their primary or key secondary endpoints or be sufficient to file for or gain regulatory approval to market a product without further development work or may not support further development at all; we may encounter adverse results or adverse events at any stage of development that negatively impact further development or that require additional nonclinical and clinical work which may not yield positive results; the FDA may ultimately decide that the design or results of our completed, ongoing and planned clinical trials for any of our product candidates, even if positive, are not sufficient for regulatory approval in the indications that are the focus of our development plan; other decisions or actions of the FDA or other regulatory agencies may affect the initiation, timing, design, size, progress and cost of clinical trials and our ability to proceed with further development; we may encounter technical and other unexpected hurdles in the development and manufacture of our product candidates which may delay our timing or change our plans or increase our costs; as well as those risks more fully discussed in the section entitled "Risk Factors" in our most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

    Get the next $SAGE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SAGE

    DatePrice TargetRatingAnalyst
    3/11/2025$5.00Underperform
    BofA Securities
    11/21/2024$4.00Underperform → Sector Perform
    RBC Capital Mkts
    10/10/2024Mkt Perform
    Raymond James
    10/4/2024$10.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    7/30/2024$16.00 → $10.00Buy → Hold
    TD Cowen
    7/25/2024$18.00 → $12.00Overweight → Neutral
    JP Morgan
    5/29/2024$15.00Neutral
    Robert W. Baird
    5/29/2024$8.00Sell
    Citigroup
    More analyst ratings

    $SAGE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

    For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

    8/8/23 9:34:19 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

    8/4/23 6:50:31 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    SEC Filings

    View All

    SEC Form 15-12G filed by Sage Therapeutics Inc.

    15-12G - Sage Therapeutics, Inc. (0001597553) (Filer)

    8/11/25 5:00:17 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Sage Therapeutics Inc.

    POSASR - Sage Therapeutics, Inc. (0001597553) (Filer)

    8/1/25 5:22:10 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Sage Therapeutics Inc.

    POSASR - Sage Therapeutics, Inc. (0001597553) (Filer)

    8/1/25 5:21:50 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SAGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $SAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

    ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage"). "Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026." Compelling Strategic Rationale Strengthens psychi

    7/31/25 8:44:03 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Announces Second Quarter 2025 Financial Results

    Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter Previously announced acquisition by Supernus Pharmaceuticals expected to close in third quarter of 2025 Cash, cash equivalents, and marketable securities of $366 million as of June 30, 2025 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. "Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our c

    7/30/25 4:05:00 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

    ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus' proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ:SAGE) ("Sage"), expired at 11:59 p.m. Eastern Time on July 25, 2025. On June 13, 2025, Supernus and Sage, entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among Supernus, Sage and Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus ("Purchaser")

    7/28/25 8:25:15 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on SAGE Therapeutics with a new price target

    BofA Securities resumed coverage of SAGE Therapeutics with a rating of Underperform and set a new price target of $5.00

    3/11/25 7:43:31 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SAGE Therapeutics upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded SAGE Therapeutics from Underperform to Sector Perform and set a new price target of $4.00

    11/21/24 7:42:56 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on SAGE Therapeutics

    Raymond James resumed coverage of SAGE Therapeutics with a rating of Mkt Perform

    10/10/24 8:30:27 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Quirk Michael C. returned 32,961 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

    7/31/25 12:04:37 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Federer Jessica

    4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

    7/31/25 12:03:01 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Benecchi Christopher returned 64,428 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

    7/31/25 11:57:08 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/14/24 6:14:58 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/12/24 4:56:16 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/12/24 10:34:18 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Financials

    Live finance-specific insights

    View All

    Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

    ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage"). "Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026." Compelling Strategic Rationale Strengthens psychi

    7/31/25 8:44:03 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Announces Second Quarter 2025 Financial Results

    Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter Previously announced acquisition by Supernus Pharmaceuticals expected to close in third quarter of 2025 Cash, cash equivalents, and marketable securities of $366 million as of June 30, 2025 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. "Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our c

    7/30/25 4:05:00 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

    Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe

    6/16/25 7:00:06 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Leadership Updates

    Live Leadership Updates

    View All

    Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously se

    6/23/25 7:59:57 AM ET
    $PHAT
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Announces R&D Leadership Transition

    Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

    3/4/25 4:15:00 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Appoints Jessica Federer to Board of Directors

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005117/en/Jessica Federer (Photo: Business Wire) "We are thrilled to have Jessica join our Board of Directors. Jessica is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Jessica's innate curiosit

    3/16/23 6:30:00 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care